The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
Number of Lawsuits Increases Fivefold to Over 2,100 Since May- FDA Approves Brain Tumour WarningGlobal pharmaceutical company Pfizer Inc. (NYSE: PFE), manufacturer of contraceptive injection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback